Insulet Corporation (PODD): Price and Financial Metrics
GET POWR RATINGS... FREE!
PODD POWR Grades
- PODD scores best on the Quality dimension, with a Quality rank ahead of 62.31% of US stocks.
- PODD's strongest trending metric is Quality; it's been moving down over the last 31 weeks.
- PODD ranks lowest in Sentiment; there it ranks in the 12th percentile.
PODD Stock Summary
- With a one year PEG ratio of 5,854.33, Insulet Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 99.2% of US stocks.
- PODD's current price/earnings ratio is 2,032.29, which is higher than 99.65% of US stocks with positive earnings.
- The price/operating cash flow metric for Insulet Corp is higher than 98.9% of stocks in our set with a positive cash flow.
- Stocks that are quantitatively similar to PODD, based on their financial statements, market capitalization, and price volatility, are NVCR, GOOD, VSAT, MMSI, and AMRN.
- PODD's SEC filings can be seen here. And to visit Insulet Corp's official web site, go to www.insulet.com.
PODD Stock Price Chart Interactive Chart >
PODD Price/Volume Stats
|Current price||$282.45||52-week high||$306.46|
|Prev. close||$281.60||52-week low||$175.35|
|Day high||$282.61||Avg. volume||523,141|
|50-day MA||$269.55||Dividend yield||N/A|
|200-day MA||$255.97||Market Cap||18.72B|
Insulet Corporation (PODD) Company Bio
Insulet Corporation develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the United States. The company was founded in 2000 and is based in Billerica, Massachusetts.
PODD Latest News Stream
|Loading, please wait...|
PODD Latest Social Stream
View Full PODD Social Stream
Latest PODD News From Around the Web
Below are the latest news stories about Insulet Corp that investors may wish to consider to help them evaluate PODD as an investment opportunity.
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the virtual BofA Securities 2021 Health Care Conference on Wednesday, May 12, 2021 at 4:15 p.m. (Eastern Time).
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the publication of its 2020 Sustainability Report. The report, which includes Insulet’s first comprehensive sustainability strategy and materiality assessment, highlights the Company’s areas of focus and performance on Environmental, Social, and Governance (ESG) issues.
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ: AXNX ) Boston Scientific Corporation (NYSE: BSX ) (reacted to first-quarter results) Celcuity Inc. (NASDAQ: CELC ) Celldex Therapeutics, Inc. (NASDAQ: CLDX) Galectin Therapeutics Inc. (NASDAQ: GALT ) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Integra LifeSciences Holdings Corporation (NASDAQ: IART ) (announced first-quarter results) Lantheus Holdings, Inc. (NASDAQ: LNTH ) MacroGenics, Inc. (NASDAQ: MGNX ) NuVasive, Inc. (NASDAQ: NUVA) PRA Health Sciences, Inc. (NASDAQ: PRAH ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Verastem, Inc. (NASDAQ: VSTM ) Down In The Dumps (Bi...
Q1'21 Earnings Release Schedule
PODD Price Returns